Close Menu

Morphosys

German technology firm Biametrics announced this week that it would expand its relationship with MorphoSys following a successful preliminary study that paired Biametrics' microarray technology with MorphoSys' therapeutic antibodies.

NEW YORK (GenomeWeb News) - Bio-Rad Laboratories said today that it has closed its acquisition of antibody manufacturer AbD Serotec, a division of MorphoSys, for around €53 million ($70 million) in cash.

NEW YORK (GenomeWeb News) – Bio-Rad Laboratories announced yesterday that it has signed a definitive agreement to acquire antibody manufacturer AbD Serotec for €53 million ($69.7 million) in cash.

Vermillion has nominated Paul Sohmer to stand for election to its board of directors at the company's upcoming board meeting.

NEW YORK (GenomeWeb News) – Danaher's board of directors approved a quarterly dividend of $.025 per share payable on Jan. 27, 2012 to holders of record on Dec. 30, 2011.

Morphosys this week presented its new antibody technology Ylanthia, the next generation of the company’s HuCAL platform.

Morphosys said it has agreed to a three-year extension of its ongoing research partnership with Japanese pharma firm Shionogi.

Morphosys announced that its AbD Serotec division has signed an agreement with the Moredun Research Institute and the University of Edinburgh's Roslin Institute to develop reagents for veterinary research.

Genedata said this week that MorphoSys has licensed Genedata Biologics, its research and development data management platform, to support efforts to develop therapeutic antibodies.

The agreement grants Merck access to the company's HuCAL Gold antibody library for research purposes, as well as the option to upgrade to Morphosys's HuCAL Platinum library.

Pages

The UK and the European Union have come to a sticking point in the negotiation of how the UK might remain involved in the Horizon Europe research program, the Guardian reports.

The New York Times reports that experts pushed during a meeting of an FDA advisory board for the agency to require more safety data from SARS-CoV-2 vaccine trials.

The Washington Post reports Moderna expects that it will have enough data on its candidate SARS-CoV-2 vaccine to submit to regulatory authorities by mid-November.

In Science this week: ANXA11 variants affect calcium homeostasis and stress granule disassembly in ALS, and more.